Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation disease BEFREE The P53 pathway is, therefore, disrupted in 81.8% of malignant gliomas (WHO grades III and IV), either by mutation of the p53 gene (31.8%) or by p14arf deletion (54.5%). 10949938 2000
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease BEFREE The highest percentage of PDGF-induced malignant gliomas arose from of Ink4a-Arf null progenitor cells. 11485986 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease BEFREE We transfected the full-length human p16 gene into p16-null human glioma cell line, U251MG cells, using the plasmid vector pRc/CMV-p16 and evaluated the effect of p16 gene transfer on the growth suppression of malignant glioma cells. 9216647 1997
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease CTD_human Genome-wide association study identifies five susceptibility loci for glioma. 19578367 2009
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression disease BEFREE Amplification of the cyclin-dependent kinase 4 (CDK4) gene, located at 12q13-q14, has been found as an alternative genetic alteration to CDKN2A inactivation in various human tumors including malignant gliomas and sarcomas. 9916925 1999
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation disease BEFREE Thirty-four to fifty-six percent of malignant gliomas harbor homozygous co-deletions of the INK4a(p16-p14ARF) and INK4b(p15) tumor suppressor genes. 11563632 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation disease BEFREE We have investigated by using quantitative polymerase chain reaction and single-strand conformation polymorphism analysis the structure of exon 2 of CDKN2 in 32 malignant gliomas. 7987825 1994
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease BEFREE To study resistance mechanisms, which include feedback activation of mitogen-activated protein kinase (MAPK) signaling in melanoma, we developed a luciferase-modified cell line (2341luc) from a BrafV600E mutant and Cdkn2a- deficient murine high-grade glioma, and analyzed its molecular responses to BRAFV600E- and MAPK kinase (MEK)-targeted inhibition. 27713119 2016
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease BEFREE Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas. 16786135 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease BEFREE Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas. 10541865 1999
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression disease BEFREE In contrast, no methylation was observed in four other malignant gliomas and two low-grade gliomas that expressed p16 protein. 8895506 1996
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease BEFREE Adenoviral p16/CDKN2 gene transfer to malignant glioma: role of p16 in growth, invasion, and senescence. 12883667 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation disease BEFREE In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma. 30972500 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression disease BEFREE Here we show that a lower expression of CDKN2A and a higher expression of cyclin D1 in the patients with high-grade malignant gliomas than low-grade gliomas, respectively. 21843312 2011
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression disease BEFREE These findings implicate p16 in the transcriptional regulation of telomerase activity by inhibiting the function of Sp1 in human malignant gliomas. 15067344 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression disease BEFREE CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma. 25921285 2015
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease BEFREE These data suggest that CDKN2A is a critical target for mutational inactivation in human malignant gliomas. 9053859 1997
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease BEFREE Recent studies have indicated that the loss of p16 is a frequent event in the progression of malignant gliomas. 10446996 1999
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation disease BEFREE In addition, the alterations of the p16 gene might not play a major role in tumorigenesis of malignant gliomas in Malaysian patients. 15679305 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease CTD_human Loss of heterozygosity at the Ink4a/Arf gene locus was observed in 5/5 malignant gliomas and 1/1 neuroblastoma, while the PTEN(phosphatase and tensin homologue) gene locus was unaffected by deletions. 15814359 2005
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease BEFREE Moreover, transduction of Ink4a/Arf(-/-) neural stem cells (NSCs) or astrocytes with constitutively active EGFR induces a common high-grade glioma phenotype. 12086863 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker disease BEFREE In addition, the low frequency of homozygous deletions shown in this study is quite different from previous reports that demonstrated frequently deleted p16 gene in malignant gliomas from Caucasian patients. 10536183 1999
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation disease BEFREE BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. 25667294 2015